US biotech outfit Ecovia Bio has secured funding to support significant expansion of manufacturing capacity at its facility in Livonia, Michigan.
Ecovia Bio hopes the expansion will help it to meet surging global demand for its AzuraBase and AzuraGel families of gamma polyglutamic acid (γ-PGA) and speciality biopolymer products across cosmetics, personal care, agriculture, and hygiene applications.
With this investment, the company projects the facility will achieve full operational capacity by 2028.
In addition, it has begun evaluation of additional production facilities to accommodate market demand beyond 2028 and secure long-term supply chain security for global partners.
Ecovia Bio says its biodegradable γ-PGA technology enables personal care product manufacturers to replace persistent synthetic polymers like microplastics with a bio-based, fully biodegradable alternative that delivers equivalent or superior performance without environmental or health consequences.
By scaling production of γ-PGA, Ecovia Bio is empowering a global shift toward truly sustainable consumer products - addressing regulatory pressures, consumer demand for safer products, and the urgent need to protect human health and environmental integrity.
The Series B funding round was led by Pointe Angels, an independent angel investor group based in the Grosse Pointe communities east of Detroit, Michigan.
"We are excited to partner with Pointe Angels," said Kousay Said, CEO of Ecovia Bio.
"This capital enables us to meet immediate demand from our cosmetics, personal care, and agricultural customers while establishing the infrastructure needed to serve the hygiene sector at industrial scale."
